Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC genito-urinary tract cancer cooperative group

Abstract Mitoxantrone at a dose of 12 mg/m 2 i.v. q 3 weeks failed to produce a response in 28 adequately treated patients with measurable advanced bladder cancer. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result the use of mitoxantrone in this disease cannot be recommended.